BCMA CAR-T cells + GPRC5D CAR-T cells

A dual-targeted cell therapy consisting of two populations of autologous or allogeneic **chimeric antigen receptor (CAR) T cells**, one targeting B-cell maturation antigen (**BCMA**) and the other targeting **G protein-coupled receptor class C group 5 member D (GPRC5D)**. This combination is being investigated primarily for the treatment of **relapsed/refractory multiple myeloma**, particularly in patients with high-risk features such as extramedullary disease. By targeting two independent antigens expressed on myeloma cells, this therapy aims to reduce the risk of antigen escape—a major mechanism for relapse after single-antigen CAR-T therapy. Early-phase clinical and preclinical studies have shown promising efficacy, with high response rates and manageable toxicity profiles. Treatment typically involves collecting T cells from the patient, genetically engineering them ex vivo to express CARs specific for either BCMA or GPRC5D, and then infusing both products, often simultaneously or sequentially[1][2][3].